Carcinoid Cancer - Pipeline Review, Q4 2010

Description: Carcinoid Cancer - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Carcinoid Cancer Pipeline Review, Q4 2010”, provides an overview of the Carcinoid Cancer therapeutic pipeline. This report provides information on the therapeutic development for Carcinoid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinoid Cancer. “Carcinoid Cancer - Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Carcinoid Cancer.
- A review of the Carcinoid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinoid Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Carcinoid Cancer.
- A review of the Carcinoid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinoid Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carcinoid Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Carcinoid Cancer
Carcinoid Cancer Therapeutics under Development by Companies
Carcinoid Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Carcinoid Cancer Therapeutics Development
Amgen Inc.
Bioniche Life Sciences, Inc.
Ipsen S.A.
Novartis AG
EntreMed, Inc.
Evotec Aktiengesellschaft
Molecular Insight Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc.
AnorMED, Inc.
Universities/Institutes Involved in Carcinoid Cancer Therapeutics Development
Carcinoid Cancer Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Somatuline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
5-hydroxy tryptophan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carcinoid Cancer - Featured News
Apr 12, 2010: Affinium Begins Phase I Clinical Trial Using Optimized Oral Formulation Of AFN-1252
Apr 12, 2010: Molecular Insight's Onalta Phase II Data Published In Journal Of Clinical Oncology
Jul 21, 2009: LX1032 Receives Orphan Drug Designation From EMEA For Carcinoid Syndrome
Jul 08, 2009: LX1032 Phase 2 Clinical Trial Initiated By Lexicon In Patients With Carcinoid Syndrome
May 27, 2009: Lexicon To Present Clinical Data For LX1032 At Digestive Disease Week
May 14, 2009: Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development of Onalta
Oct 23, 2008: Exelixis Reports Positive Phase 1 Data For XL281 At EORTC-NCI-AACR Symposium
Jun 18, 2008: Molecular Insight Pharmaceuticals, Inc. Reports Onalta Tissue Distribution Data Support Clinical Development Program
May 16, 2008: Callisto Pharmaceuticals Reports Promising Interim Phase II Data For Atiprimod In Advanced Carcinoid Cancer
Apr 14, 2008: Callisto Pharmaceuticals Announces Interim Data Of Phase II Clinical Trial Of Atiprimod In Advanced Carcinoid Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information

Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Carcinoid Cancer - Pipeline Review, Q4 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/1474114/">http://www.researchandmarkets.com/reports/1474114/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2LPWU</td>
</tr>
</tbody>
</table>

Product Formats

Please select the product formats and quantity you require:

- Electronic (PDF) - Single User: $500
- Electronic (PDF) - Site License: $1000
- Electronic (PDF) - Enterprisewide: $1500

Contact Information

Please enter all the information below in BLOCK CAPITALS

- Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
- First Name: ____________________________ Last Name: ____________________________
- Email Address: * ____________________________
- Job Title: ____________________________
- Organisation: ____________________________
- Address: ____________________________
- City: ____________________________
- Postal / Zip Code: ____________________________
- Country: ____________________________
- Phone Number: ____________________________
- Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World